Compare · CBLL vs LIVN
CBLL vs LIVN
Side-by-side comparison of CeriBell Inc. (CBLL) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.32B, about 6.3x CBLL ($689.8M).
- Over the past year, CBLL is down 0.4% and LIVN is up 72.6% - LIVN leads by 73.0 points.
- LIVN has been more active in the news (16 items in the past 4 weeks vs 10 for CBLL).
- LIVN has more recent analyst coverage (20 ratings vs 8 for CBLL).
- Company
- CeriBell Inc.
- LivaNova PLC
- Price
- $18.39+1.27%
- $78.66-0.08%
- Market cap
- $689.8M
- $4.32B
- 1M return
- -1.79%
- +6.80%
- 1Y return
- -0.41%
- +72.62%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- News (4w)
- 10
- 16
- Recent ratings
- 8
- 20
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest CBLL
- Director Taylor Joseph Michael sold $101,255 worth of shares (5,500 units at $18.41), decreasing direct ownership by 8% to 61,573 units (SEC Form 4)
- President and CEO Chao Xingjuan sold $714,870 worth of shares (39,000 units at $18.33) as part of a pre-agreed trading plan and exercised 25,000 shares at a strike of $4.70, decreasing direct ownership by 2% to 816,317 units (SEC Form 4)
- Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
- Director Tammenoms Bakker Juliet was granted 7,838 shares, increasing direct ownership by 51% to 23,284 units (SEC Form 4)
- Director Parvizi Josef was granted 7,838 shares, increasing direct ownership by 51% to 23,284 units (SEC Form 4)
- Director Rogers Erica J. was granted 7,838 shares, increasing direct ownership by 31% to 33,054 units (SEC Form 4)
- Director Burke William W was granted 7,838 shares, increasing direct ownership by 45% to 25,229 units (SEC Form 4)
- Director Taylor Joseph Michael was granted 7,838 shares, increasing direct ownership by 13% to 67,073 units (SEC Form 4)
- Director Robertson Rebecca B was granted 7,838 shares, increasing direct ownership by 42% to 26,587 units (SEC Form 4)
- CeriBell Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest LIVN
- Director Wilver Peter M covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 53% to 10,294 units (SEC Form 4)
- Chief Innovation Officer Tezel Ahmet converted options into 2,965 units of Ordinary Shares and covered exercise/tax liability with 1,032 units of Ordinary Shares, increasing direct ownership by 46% to 6,090 units (SEC Form 4)
- Director Bianchi Francesco covered exercise/tax liability with 486 units of Ordinary Shares, sold $96,228 worth of Ordinary Shares (1,200 units at $80.19) and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 33% to 9,584 units (SEC Form 4)
- Director Podlogar Susan M converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 170% to 5,642 units (SEC Form 4)
- Director Schermerhorn Todd C converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 39% to 12,619 units (SEC Form 4)
- SEC Form 4 filed by Director Nygaard-Andersen Jette
- Director Enxing Seng Stacy converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 30% to 15,307 units (SEC Form 4)
- Director Kozy William A converted options into 5,681 units of Ordinary Shares and covered exercise/tax liability with 682 units of Ordinary Shares, increasing direct ownership by 15% to 37,566 units (SEC Form 4)
- Director Barry James Christopher covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 82% to 7,918 units (SEC Form 4)
- Director Story Brooke covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 57% to 9,788 units (SEC Form 4)